<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079219</url>
  </required_header>
  <id_info>
    <org_study_id>SYM010</org_study_id>
    <nct_id>NCT03079219</nct_id>
  </id_info>
  <brief_title>Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients</brief_title>
  <official_title>A Randomized Study to Determine the Efficacy and Tolerability of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CCTU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Olanzapine Regimen will be superior to the Standard Regimen, as measured by the
      proportion of patients with Complete Response in the 120 hours following AC chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of episodes of nausea in the first 120 hours after first cycle of chemotherapy.</measure>
    <time_frame>120 hours</time_frame>
    <description>Number of episodes of nausea in the first 120 hours after first cycle of chemotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of episodes of vomiting in the first 120 hours after first cycle of chemotherapy.</measure>
    <time_frame>120 hours</time_frame>
    <description>Number of episodes of vomiting in the first 120 hours after first cycle of chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of nausea in the first 120 hours during 4 cycles of chemotherapy.</measure>
    <time_frame>120 hours</time_frame>
    <description>Number of episodes of nausea in the first 120 hours during 4 cycles of chemotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of vomiting in the first 120 hours during 4 cycles of chemotherapy.</measure>
    <time_frame>120 hours</time_frame>
    <description>Number of episodes of vomiting in the first 120 hours during 4 cycles of chemotherapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant, Ondansetron, Dexamethasone and Olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aprepitant, Ondansetron, Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental drug: Aprepitant</intervention_name>
    <description>Day 1: 125mg QD; Day 2 to Day 3: 80mg QD</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental drug: Ondansetron</intervention_name>
    <description>Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental drug: Dexamethasone</intervention_name>
    <description>Day 1: 12mg QD</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental drug: Olanzapine</intervention_name>
    <description>Day 1 to Day 5: 10mg QD</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard: Aprepitant</intervention_name>
    <description>Day 1: 125mg QD, Day 2 to Day3: 80mg QD</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard: Ondansetron</intervention_name>
    <description>Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard: Dexamethasone</intervention_name>
    <description>Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese patient, female &gt;=18 and &lt; 75 years of age.

          -  Patient is diagnosed with early breast cancer.

          -  Patient is na√Øve to emetogenic chemotherapy moderately or highly emetogenecity.

          -  Patient is scheduled to receive her first course of adjuvant chemotherapy for breast
             cancer follows:

          -  IV adriamycin 60 mg/m2 + cyclophosphamide 600 mg/m2

          -  Patient has a predicted life expectancy of &gt;=4 months.

          -  Patient has ECOG Performance Status of 0-1

          -  Premenopausal female patients must not be pregnant (documented negative urine
             pregnancy test).

          -  Patient is able to read, understand and complete study questionnaires and diary,
             including questions requiring a visual analog scale (VAS) response.

          -  Patient understands the procedures and agrees to participate in the study by giving
             written informed consent

        Exclusion Criteria:

          -  Patient with advanced breast cancer.

          -  Patient receiving cisplatin or any other chemotherapy of higher emetogenic potential,
             except for cyclophosphamide and doxorubicin in the regimens described above.

          -  Patients who are scheduled to receive concurrent radiation as part of their
             chemotherapy regimen for their malignancy

          -  Patients who experience any vomiting or grade 2-3 nausea per Common Terminology
             Criteria for Adverse Events version 4.0 (CTCAE v 4.03) in the 24 hours before Day 1 of
             chemotherapy

          -  Patient has a history of treatment with moderately to highly emetogenic chemotherapy.

          -  Patient has an active infection (e.g., pneumonia, systemic fungal infection) or any
             uncontrolled disease (e.g., diabetes mellitus, hypertension) which, in the opinion of
             the investigator, might confound the results of the study or pose unwarranted risk.

          -  Patient with history of glaucoma, dementia, seizures, Parkinson's disease, Neuroleptic
             Malignant Syndrome (NMS), thromboembolic events.

          -  Patient currently uses any illicit drugs, including marijuana, or has current evidence
             of alcohol abuse as determined by the investigator.

          -  Patient is mentally incapacitated or has a significant emotional or psychiatric
             disorder that, in the opinion of the investigator, precludes study entry.

          -  Patients who are regular alcohol drinker or smoker

          -  Patient has a history of any illness that, in the opinion of the investigator, might
             confound the results of the study or pose unwarranted risk.

          -  Patient has a history of hypersensitivity to aprepitant, ondansetron or dexamethasone.

          -  Patients who have phenylketonuria and abnormal uric acid.

          -  Any investigational drugs taken within 4 weeks prior to Day 1 of cycle 1, and/or is
             scheduled to receive any investigational drug during the study;

          -  Patient is taking systemic corticosteroid therapy at any dose; however, topical and
             inhaled corticosteroids are permitted.

          -  Patient has taken a non-registered investigational drug within the 28 days of the
             Prestudy Visit.

          -  Use, in the 28 days prior to Treatment Day 1, of barbiturates, rifampicin or
             rifabutin, phenytoin or carbamazepine

          -  Use, in the 7 days prior to Treatment Day 1, of terfenadine, cisapride, astemizole,
             clarithromycin (azithromycin, erythromycin and roxithromycin are permitted),
             ketoconazole or itraconazole (fluconazole is permitted), amifostine pimozide 5-HT3
             antagonists (ondansetron, granisetron, dolasetron, or tropisetron) phenothiazines
             (e.g., prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or
             chlorpromazine) butyrophenones (e.g., haloperidol or droperidol) benzamides (e.g.,
             metoclopramide or alizapride) domperidone cannabinoids NK1 receptor antagonists

          -  Use, in the 48 hours prior to Treatment Day 1, of benzodiazepines or opiates, except
             for single daily doses of lorazepam.

             s. Use of the following drugs: carbamazepine Fluvoxamine ciprofloxacin dopamine
             agonists. antiparkinsonian medicinal products medicinal products known to increase QTc
             interval t. Abnormal laboratory values
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Winnie Yeo, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Winnie Yeo, MD, FRCP</last_name>
    <phone>3505 2118</phone>
    <email>winnie@clo.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong LAI, RN</last_name>
    <phone>3505 1138</phone>
    <email>dong@clo.cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Winnie Yeo, MD, FRCP</last_name>
      <phone>3505 2118</phone>
      <email>winnie@clo.cuhk.edu.hk</email>
    </contact>
    <contact_backup>
      <last_name>Dong LAI, RN</last_name>
      <phone>3505 1138</phone>
      <email>dong@clo.cuhk.edu.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

